Current reports
6-K
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
25 Apr 24
6-K
Virax Biolabs Group Limited to Participate at ESCMID Global 2024
16 Apr 24
6-K
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
15 Mar 24
6-K
Current report (foreign)
22 Jan 24
6-K
Current report (foreign)
12 Jan 24
6-K
Current report (foreign)
21 Dec 23
6-K
Current report (foreign)
20 Dec 23
6-K
Virax Biolabs’ CEO James Foster Issues Letter to Shareholders
18 Dec 23
6-K
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
14 Dec 23
6-K
Current report (foreign)
8 Dec 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Jan 24
424B3
Prospectus supplement
20 Dec 23
424B3
Prospectus supplement
20 Dec 23
F-3
Shelf registration (foreign)
5 Dec 23
D
$2.15 mm in equity / options / securities to be acquired, sold $2.15 mm, 1 investor
17 Oct 23
424B3
Prospectus supplement
31 Mar 23
F-1
Registration statement (foreign)
22 Mar 23
D
$4.00 mm in equity / options / securities to be acquired, sold $4.00 mm, 1 investor
15 Mar 23
424B3
Prospectus supplement
2 Dec 22
F-1
Registration statement (foreign)
18 Nov 22
Proxies
No filings
Other
EFFECT
Notice of effectiveness
18 Dec 23
CORRESP
Correspondence with SEC
13 Dec 23
UPLOAD
Letter from SEC
12 Dec 23
EFFECT
Notice of effectiveness
30 Mar 23
UPLOAD
Letter from SEC
28 Mar 23
CORRESP
Correspondence with SEC
28 Mar 23
EFFECT
Notice of effectiveness
2 Dec 22
CORRESP
Correspondence with SEC
29 Nov 22
UPLOAD
Letter from SEC
25 Nov 22
CERT
Certification of approval for exchange listing
20 Jul 22
Ownership